靶向肠-肝-免疫轴治疗肝硬化
该综述聚焦肝硬化相关免疫功能障碍(CAID)与肠道菌群失调、肠屏障功能受损及黏膜免疫稳态缺陷之间的关联,讨论恢复肠道真杆菌群、增强肠屏障功能及改善黏膜与全身免疫缺陷的已有和新兴治疗策略。
要点
- 肝硬化门脉高压的失代偿事件(腹水、脑病、门脉高压性出血、肝肾综合征)发生于CAID背景下,决定发病率与预后。
- CAID表现为全身免疫细胞处于致敏状态并呈炎症表型,但对病原体攻击不能产生强健应答。
- 细菌感染(含自发性腹膜炎)常源于肠道微生物,与晚期慢性肝病肠道共生菌群失调密切相关。
核心结论
- 综述梳理了肝硬化菌群失调、肠屏障功能障碍与宿主-微生物区隔化及黏膜免疫稳态缺陷之间的关联,并讨论了针对恢复肠道真杆菌群、增强肠屏障功能及改善黏膜与全身免疫缺陷的已有和新兴治疗策略。
研究设计与样本
- 综述,检索范围原文未报告。
主要发现
- 肝硬化门脉高压以腹水、脑病、门脉高压性出血和肝肾综合征等失代偿事件为特征,这些事件发生于CAID背景下并决定发病率与预后。
- CAID描述全身免疫细胞处于致敏状态并呈炎症表型、同时对病原体攻击不能产生强健应答的双向观察。
- 细菌感染包括自发性腹膜炎是晚期慢性肝病常见并发症,可诱发静脉曲张出血、肝肾综合征和慢加急性肝衰竭。
- 细菌感染常源于肠道微生物,并与晚期慢性肝病肠道共生菌群失调密切相关。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Cirrhotic portal hypertension is characterised by development of the decompensating events of ascites, encephalopathy, portal hypertensive bleeding and hepatorenal syndrome, which arise in a setting of cirrhosis-associated immune dysfunction (CAID) and define morbidity and prognosis. CAID describes the dichotomous observations that systemic immune cells are primed and display an inflammatory phenotype, while failing to mount robust responses to pathogen challenge. Bacterial infections including spontaneous bacterial peritonitis are common complications of advanced chronic liver disease and can precipitate variceal haemorrhage, hepatorenal syndrome and acute-on-chronic liver failure; they frequently arise from gut-derived organisms and are closely linked with dysbiosis of the commensal intestinal microbiota in advanced chronic liver disease.Here, we review the links between cirrhotic dysbiosis, intestinal barrier dysfunction and deficits of host-microbiome compartmentalisation and mucosal immune homoeostasis that occur in settings of advanced chronic liver disease. We discuss established and emerging therapeutic strategies targeted at restoring intestinal eubiosis, augmenting gut barrier function and ameliorating the mucosal and systemic immune deficits that characterise and define the course of decompensated cirrhosis.
引用
- Tranah TH, Edwards LA, Schnabl B, et al. Targeting the gut-liver-immune axis to treat cirrhosis. Gut. 2020. PMID: 33060124. doi:10.1136/gutjnl-2020-320786
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。